Patients receive EF5 IV over 1-2.5 hours on day 1 and motexafin lutetium IV over 10-15 minutes on day 2. Patients undergo definitive surgical resection approximately 3 hours after motexafin lutetium administration. Hypoxia and motexafin lutetium levels in the resected tumors are evaluated. Tumor to normal tissue ratios are also determined.

Advanced Adult Primary Liver Cancer

Carcinoma of the Appendix

Fallopian Tube Cancer

Gastrointestinal Stromal Tumor

Localized Extrahepatic Bile Duct Cancer

Localized Gallbladder Cancer

Localized Gastrointestinal Carcinoid Tumor

Localized Resectable Adult Primary Liver Cancer

Localized Unresectable Adult Primary Liver Cancer

Metastatic Gastrointestinal Carcinoid Tumor

Ovarian Sarcoma

Ovarian Stromal Cancer

Primary Peritoneal Cavity Cancer

Recurrent Adult Primary Liver Cancer

Recurrent Adult Soft Tissue Sarcoma

Recurrent Colon Cancer

Recurrent Extrahepatic Bile Duct Cancer

Recurrent Gallbladder Cancer

Recurrent Gastric Cancer

Recurrent Gastrointestinal Carcinoid Tumor

Recurrent Non-small Cell Lung Cancer

Recurrent Ovarian Epithelial Cancer

Recurrent Ovarian Germ Cell Tumor

Recurrent Pancreatic Cancer

Recurrent Rectal Cancer

Recurrent Small Intestine Cancer

Recurrent Uterine Sarcoma

Regional Gastrointestinal Carcinoid Tumor

Small Intestine Adenocarcinoma

Small Intestine Leiomyosarcoma

Small Intestine Lymphoma

Stage 0 Non-small Cell Lung Cancer

Stage I Adult Soft Tissue Sarcoma

Stage I Colon Cancer

Stage I Gastric Cancer

Stage I Non-small Cell Lung Cancer

Stage I Ovarian Epithelial Cancer

Stage I Ovarian Germ Cell Tumor

Stage I Pancreatic Cancer

Stage I Rectal Cancer

Stage I Uterine Sarcoma

Stage II Adult Soft Tissue Sarcoma

Stage II Colon Cancer

Stage II Gastric Cancer

Stage II Non-small Cell Lung Cancer

Stage II Ovarian Epithelial Cancer

Stage II Ovarian Germ Cell Tumor

Stage II Pancreatic Cancer

Stage II Rectal Cancer

Stage II Uterine Sarcoma

Stage III Adult Soft Tissue Sarcoma

Stage III Colon Cancer

Stage III Gastric Cancer

Stage III Ovarian Epithelial Cancer

Stage III Ovarian Germ Cell Tumor

Stage III Pancreatic Cancer

Stage III Rectal Cancer

Stage III Uterine Sarcoma

Stage IIIA Non-small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer

Stage IV Adult Soft Tissue Sarcoma

Stage IV Colon Cancer

Stage IV Gastric Cancer

Stage IV Non-small Cell Lung Cancer

Stage IV Ovarian Epithelial Cancer

Stage IV Ovarian Germ Cell Tumor

Stage IV Pancreatic Cancer

Stage IV Rectal Cancer

Stage IV Uterine Sarcoma

Unresectable Extrahepatic Bile Duct Cancer

Unresectable Gallbladder Cancer

motexafin lutetium

pharmacological study

Abramson Cancer Center of The University of Pennsylvania

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

Distribution Of The Photosensitizer Motexafin Lutetium And Hypoxia In Patients With Malignancies

Data will be described using graphical techniques (e.g., box plots) and summary statistics (e.g., means, medians, standard deviations, and interquartile ranges). For each patient, the mean concentration of motexafin lutetium across tumor and normal samples will be summarized.

Summary data for each patient will be used to construct a TNTR. Wilcoxon signed rank test of whether the median ration exceeds will be carried out.

Will be graded, tabled for each stratum and for the entire study and summarized by frequencies and percentages.

National Cancer Institute (NCI)

lutetium

hypoxia

lutetium/hypoxia

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus